I see_老虎社区_美港股上老虎

2021-12-01

I see

Bionano Genomics Proves Not Everything Genetic is Gold

免责声明：上述内容仅代表发帖人个人观点，不构成本平台的任何投资建议。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"detailType":1,"isChannel":false,"data":{"magic":2,"id":603947489,"tweetId":"603947489","gmtCreate":1638358841076,"gmtModify":1638358841313,"author":{"id":3582199304143416,"idStr":"3582199304143416","authorId":3582199304143416,"authorIdStr":"3582199304143416","name":"sgrs","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":9,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"extraTitle":"","html":"<html><head></head><body>I see</body></html>","htmlText":"<html><head></head><body>I see</body></html>","text":"I see","highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":0,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/603947489","repostId":1159950155,"repostType":4,"repost":{"id":"1159950155","kind":"news","pubTimestamp":1638358466,"share":"https://www.laohu8.com/m/news/1159950155?lang=&edition=full","pubTime":"2021-12-01 19:34","market":"us","language":"en","title":"Bionano Genomics Proves Not Everything Genetic is Gold","url":"https://stock-news.laohu8.com/highlight/detail?id=1159950155","media":"InvestorPlace","summary":"Genomics is the coming thing, but BNGO stock investors want to see the money","content":"The tech underpinning&nbsp;Bionano Genomics(NASDAQ:BNGO) stock is a cool genomics sequencing device called&nbsp;Saphyr. It claims to do genomic mapping faster, and better, than ever before possible. The machine costs$150,000, but it’s offered as a service for as little as $950 per sample.\nBionano’s&nbsp;third-quarter report&nbsp;showed 141 Saphyr devices had been installed as of the end of September,24 in the third quarter alone.&nbsp;New hires in the sales department made future prospects look good.\nBuy, buy, buy,right? Nope. Sell, sell, sell. Since a speculative spike in February sent the stock to $15.57, it has gone nowhere but down. It closed out November at $3.91 a share. That’s still up on the year, but the trend is not in your favor.\nSeeking Value in BNGO Stock\nEven at its current price, Bionano is an expensive stock.\nSales for the first three quarters of 2021 were up 250% from a year ago. But they totaled less than $11.7 million. Operating losses were also up 76%, to over $48 million. The company was still putting $6.5 million into research expenses during the third quarter. Sales and general administrative expenses have nearly doubled from a year ago.\nThere is promise here. Our Chris Tyler remains&nbsp;bullish.So doesLouis Navellier. The stock may be down, but the science is sound.\nTrouble is, if all that is true, why won’t Cathie Woods’ ARK Invest buy in? I checked the&nbsp;ARK Genomic Revolution ETF(NYSEARCA:ARKG) before writing this. It has no investments in BNGO stock. That’s bad. What’s worse is that ARKG shares themselves are down nearly a third since June. They were trading at $63.37 on Nov. 30 from $93.01 in late June.\nWhat investors seem to be saying is: Don’t show us the tech, show us the money.\nThe Market Reality\nI have been pounding the table for two years now on&nbsp;DNA as a programming language.&nbsp;It’s a coming thing.\nBut devices like the Saphyr aren’t where the money is. Big equipment purchases are carefully considered against hospital and research institution budgets. An institution is going to do a lot of tests before it makes the capital commitment. Even after you buy the Saphyr system, you’re going to be spending $450/test for reagents. In the near term, it’s Bionano’s&nbsp;services business&nbsp;that holds the most promise. Even at $1,000 per test, it takes a lot of tests to justify a market cap of $1.15 billion.\nAll the analysts tracked by&nbsp;TipRanks&nbsp;say&nbsp;“buy.”. The problem is there are only three of them. The analysis to me looks one-sided. Analysts are in the business of selling stock. A legitimate company like Bionano isn’t going to have people talking it down until there’s real news.\nThat’s why writers like our Joseph Nograles are&nbsp;advising caution.Speculators are fleeing the sector. Even the current stock price makes no sense, from the point of view of value. Hope can be found in some recent hires from&nbsp;Illumina(NASDAQ:ILMN), a mature&nbsp;genetics testing outfitwith a market capitalization of nearly $58 billion and positive earnings. But that’s just hope.\nThe Bionano Bottom Line\nBionano is not going to be a quick hit. It’s not going to make you rich in the next year unless there’s another flood of speculation in the sector.\nBut this is a solid technology with&nbsp;good growth prospects.If you like the sector, keep an eye on it. Keep an eye on exchange-traded funds like ARKG, as well. When the ETF makes a decisive move higher, that’s when you can look at Bionano. Until then I think you’re overpaying.","source":"lsy1606302653667","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Bionano Genomics Proves Not Everything Genetic is Gold</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBionano Genomics Proves Not Everything Genetic is Gold\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-12-01 19:34 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://investorplace.com/2021/12/bionano-genomics-proves-not-everything-genetic-is-gold/>InvestorPlace</a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\nThe tech underpinning Bionano Genomics(NASDAQ:BNGO) stock is a cool genomics sequencing device called Saphyr. It claims to do genomic mapping faster, and better, than ever before possible. The machine...\n\n<a href=\"https://investorplace.com/2021/12/bionano-genomics-proves-not-everything-genetic-is-gold/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BNGO":"Bionano Genomics"},"source_url":"https://investorplace.com/2021/12/bionano-genomics-proves-not-everything-genetic-is-gold/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1159950155","content_text":"The tech underpinning Bionano Genomics(NASDAQ:BNGO) stock is a cool genomics sequencing device called Saphyr. It claims to do genomic mapping faster, and better, than ever before possible. The machine costs$150,000, but it’s offered as a service for as little as $950 per sample.\nBionano’s third-quarter report showed 141 Saphyr devices had been installed as of the end of September,24 in the third quarter alone. New hires in the sales department made future prospects look good.\nBuy, buy, buy,right? Nope. Sell, sell, sell. Since a speculative spike in February sent the stock to $15.57, it has gone nowhere but down. It closed out November at $3.91 a share. That’s still up on the year, but the trend is not in your favor.\nSeeking Value in BNGO Stock\nEven at its current price, Bionano is an expensive stock.\nSales for the first three quarters of 2021 were up 250% from a year ago. But they totaled less than $11.7 million. Operating losses were also up 76%, to over $48 million. The company was still putting $6.5 million into research expenses during the third quarter. Sales and general administrative expenses have nearly doubled from a year ago.\nThere is promise here. Our Chris Tyler remains bullish.So doesLouis Navellier. The stock may be down, but the science is sound.\nTrouble is, if all that is true, why won’t Cathie Woods’ ARK Invest buy in? I checked the ARK Genomic Revolution ETF(NYSEARCA:ARKG) before writing this. It has no investments in BNGO stock. That’s bad. What’s worse is that ARKG shares themselves are down nearly a third since June. They were trading at $63.37 on Nov. 30 from $93.01 in late June.\nWhat investors seem to be saying is: Don’t show us the tech, show us the money.\nThe Market Reality\nI have been pounding the table for two years now on DNA as a programming language. It’s a coming thing.\nBut devices like the Saphyr aren’t where the money is. Big equipment purchases are carefully considered against hospital and research institution budgets. An institution is going to do a lot of tests before it makes the capital commitment. Even after you buy the Saphyr system, you’re going to be spending $450/test for reagents. In the near term, it’s Bionano’s services business that holds the most promise. Even at $1,000 per test, it takes a lot of tests to justify a market cap of $1.15 billion.\nAll the analysts tracked by TipRanks say “buy.”. The problem is there are only three of them. The analysis to me looks one-sided. Analysts are in the business of selling stock. A legitimate company like Bionano isn’t going to have people talking it down until there’s real news.\nThat’s why writers like our Joseph Nograles are advising caution.Speculators are fleeing the sector. Even the current stock price makes no sense, from the point of view of value. Hope can be found in some recent hires from Illumina(NASDAQ:ILMN), a mature genetics testing outfitwith a market capitalization of nearly $58 billion and positive earnings. But that’s just hope.\nThe Bionano Bottom Line\nBionano is not going to be a quick hit. It’s not going to make you rich in the next year unless there’s another flood of speculation in the sector.\nBut this is a solid technology with good growth prospects.If you like the sector, keep an eye on it. Keep an eye on exchange-traded funds like ARKG, as well. When the ETF makes a decisive move higher, that’s when you can look at Bionano. Until then I think you’re overpaying.","news_type":1},"isVote":1,"tweetType":1,"viewCount":364,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"CN","currentLanguage":"CN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":4,"xxTargetLangEnum":"ZH_CN"},"commentList":[],"isCommentEnd":true,"isTiger":false,"isWeiXinMini":false,"url":"/m/post/603947489"}